Wealth Enhancement Advisory Services LLC Buys New Shares in Genmab A/S Sponsored ADR $GMAB

Wealth Enhancement Advisory Services LLC bought a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,685 shares of the company's stock, valued at approximately $257,000.

A number of other hedge funds have also recently made changes to their positions in the business. GAMMA Investing LLC increased its holdings in Genmab A/S by 1,465.3% in the 1st quarter. GAMMA Investing LLC now owns 33,482 shares of the company's stock valued at $656,000 after acquiring an additional 31,343 shares during the last quarter. Park Avenue Securities LLC purchased a new stake in shares of Genmab A/S in the first quarter worth about $276,000. Fifth Third Bancorp lifted its position in shares of Genmab A/S by 16.6% in the first quarter. Fifth Third Bancorp now owns 42,151 shares of the company's stock worth $825,000 after buying an additional 6,015 shares in the last quarter. QRG Capital Management Inc. lifted its position in shares of Genmab A/S by 213.7% in the first quarter. QRG Capital Management Inc. now owns 74,847 shares of the company's stock worth $1,465,000 after buying an additional 50,990 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in shares of Genmab A/S by 169.9% during the 1st quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock valued at $145,000 after acquiring an additional 4,666 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on GMAB. Truist Financial lifted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Weiss Ratings reissued a "hold (c)" rating on shares of Genmab A/S in a research note on Wednesday. Wall Street Zen raised Genmab A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 26th. Zacks Research raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 2nd. Finally, HC Wainwright increased their price target on Genmab A/S from $36.00 to $40.00 and gave the company a "buy" rating in a report on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $40.80.

Genmab A/S Stock Performance

Genmab A/S stock opened at $31.85 on Friday. The company has a 50 day moving average price of $26.66 and a 200-day moving average price of $22.78. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $33.63. The company has a market capitalization of $20.45 billion, a PE ratio of 16.01, a P/E/G ratio of 1.85 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. On average, analysts forecast that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.